Phase 2 RCT in 100 patients with refractory metastatic anal canal squamous cell carcinoma: adding ipilimumab to nivolumab did not significantly improve median PFS (3.7 vs 2.9 months; HR 0.86, P=.25); grade ≥3 treatment-related AEs 25% vs 12%.
RCTn = 100
Morris et al. NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal